38 results on '"Masharova AA"'
Search Results
2. Pharmacokinetics of Proton Pump Inhibitors and Psychical Status of Patient as the Factors Influencing to Efficacy of GERD Treatment
- Author
-
Leonid Lazebnik, Svetlana Silvestrova, Masharova Aa, Ludmila D. Firsova, and Dmitry S. Bordin
- Subjects
Hepatology ,Pharmacokinetics ,business.industry ,Gastroenterology ,GERD ,Medicine ,Pharmacology ,business ,medicine.disease - Published
- 2011
- Full Text
- View/download PDF
3. T1122 The National Survey of Prevalence of Gastroesophageal Reflux Disease in Russia
- Author
-
Masharova Aa, Leonid Lazebnik, and Dmitry S. Bordin
- Subjects
education.field_of_study ,medicine.medical_specialty ,Lung ,Hepatology ,business.industry ,medicine.medical_treatment ,Population ,Gastroenterology ,Reflux ,Heartburn ,medicine.disease ,digestive system diseases ,medicine.anatomical_structure ,Bolus (medicine) ,Internal medicine ,medicine ,GERD ,Lung transplantation ,Population study ,medicine.symptom ,education ,business - Abstract
AIM: There is a recognized relationship between acid reflux and allograft dysfunction in the lung transplant population. The occurrence and effect of reflux is not known in the pretransplant population, although it has been speculated to occur more frequently and even play a role in progression of end-stage lung disease. With the development of ImpedancepH testing to identify both acid and non-acid reflux (NAR), we aimed to characterize reflux disease in the end-stage lung disease, pre-transplant population. METHODS: We performed a retrospective analysis of the multichannel intraluminal impedance-pH studies of 47 VA patients undergoing pre-lung transplant reflux evaluation. RESULTS: There was no significant difference in the acid exposure data between established normals and the pre-lung transplant patients who were either on or off acid suppression therapy; the average percent time of acid reflux for all patients on and off acid suppression was 1.27%, (normal BID PPI < 1.3%; p = 0.54). The combined average number of acid reflux events for those on and off acid suppressive medication was 15.6, which was no different from that expected on maximal PPI (normal BID PPI < 12 events; p =0.09). Impedance data demonstrated the mean percent of all reflux events reaching the proximal esophagus was increased in the study population (44% in study vs. 34% in normal; p = 0.00003). The mean bolus transit times (BTT) in both groups on and off of acid suppression were prolonged at 12.6 seconds in comparison with the normal median (median normal = 7.9 seconds; p < 0.00001). However, this was not statistically different from the upper limit of normal (95th percentile). Symptoms of laryngo-pharyngeal reflux (LPR) were more prevalent than classic GERD symptoms. The most common symptoms were cough (28%), belch (16%), and heartburn (14%); reflux episodes were predominantly silent and correlated (positive symptoms index) with belch only but not cough or heartburn. CONCLUSIONS: Despite normal reflux patterns in the distal esophagus, patients with end-stage lung disease have an increased frequency of NAR reaching the proximal esophagus and increased bolus contact time. This suggests that proximal reflux frequency is increased in the lung transplantation population despite normal distal reflux patterns and functions as a risk for lung damage by increasing the frequency of aspiration events.
- Published
- 2010
- Full Text
- View/download PDF
4. T1689 Heterogeneity of Nitric Oxide Synthase in Distal Esophagus of Patients With Gastroesophageal Reflux Disease
- Author
-
Tatiana S. Kozhurina, Victoria A. Kim, Dmitry S. Bordin, Elen R. Valitova, Tkachenko Ev, Drozdov Vn, Alexander V. Petrakov, Varvanina Gg, Leonid Lazebnik, and Masharova Aa
- Subjects
medicine.medical_specialty ,Hepatology ,biology ,business.industry ,Gastroenterology ,Reflux ,Disease ,Nitric oxide synthase ,Internal medicine ,medicine ,biology.protein ,business ,Distal esophagus - Published
- 2010
- Full Text
- View/download PDF
5. [Chronic gastritis: a modern look at the old problem].
- Author
-
Bodrin DS, Masharova AA, and Khomiriki SG
- Subjects
- Chronic Disease, Gastritis microbiology, Helicobacter Infections diagnosis, Helicobacter Infections microbiology, Helicobacter Infections pathology, Helicobacter Infections physiopathology, Helicobacter Infections therapy, Helicobacter pylori, Humans, Gastritis diagnosis, Gastritis pathology, Gastritis physiopathology, Gastritis therapy
- Published
- 2012
6. [Surgical treatment of neuromuscular diseases of the esophagus].
- Author
-
Vasnev OS, Nikanorov AV, Kim DO, Masharova AA, and Ianova OB
- Subjects
- Esophageal Achalasia diagnosis, Esophageal Achalasia physiopathology, Female, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux physiopathology, Gastrointestinal Motility physiology, Humans, Laparoscopy, Male, Manometry, Middle Aged, Pressure, Scleroderma, Systemic diagnosis, Scleroderma, Systemic physiopathology, Treatment Outcome, Esophageal Achalasia surgery, Fundoplication methods, Gastroesophageal Reflux surgery, Scleroderma, Systemic surgery
- Abstract
Surgical treatment of patients with neuromuscular diseases of the esophagus is a separate issue, and the approach to antireflux surgery they differ from fundoplication for gastroesophageal reflux disease. At the Central Research Institute of Gastroenterology in 2010 yr were 17 patients with neuromuscular diseases of the esophagus laparoscopic fundoplication. Analysis of results showed the effectiveness of laparoscopic fundoplication in patients with severe esophageal motility.
- Published
- 2011
7. [Pharmacoeconomic analysis of treatment of certain diseases of the digestive system].
- Author
-
Parfenov AI, Vasil'ev IuV, Il'chenko AA, Guseĭn-Zade MG, Kniazev OV, Ruchkina IN, Efremov LI, Orlova IuN, Bystrovskaia EV, Masharova AA, Li IA, Deliukina OV, Kozhurina TS, and Lazebnik LB
- Subjects
- Cost-Benefit Analysis, Digestive System Diseases drug therapy, Humans, Russia, Digestive System Diseases economics, Digestive System Diseases therapy, Economics, Pharmaceutical, Health Care Costs trends
- Abstract
The article provides data of the pharmacoeconomic analysis (cost/effectiveness) of treatment of peptic ulcer, ulcerative colitis, Crohn's disease, gastroesophageal reflux disease, biliary sludge and cholelithiasis. It was shown that the most appropriate treatment scheme is one that characterized by lower costs per unit of effectiveness. Analysis of cost/effectiveness can give an economic assessment of clinical efficacy, compare alternative treatments and help to choose the method by which the efficiency increases faster than the level of costs.
- Published
- 2011
8. [Panum (pantoprazole) effectiveness in the treatment of patients with GERD].
- Author
-
Masharova AA, Ianova OB, Valitova ÉR, Kim VA, and Zelenkin SA
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles adverse effects, Adolescent, Adult, Aged, Esophagitis, Peptic metabolism, Female, Gastroesophageal Reflux metabolism, Humans, Male, Middle Aged, Pantoprazole, Proton Pump Inhibitors adverse effects, Remission Induction, 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage, Algorithms, Esophagitis, Peptic drug therapy, Gastroesophageal Reflux drug therapy, Proton Pump Inhibitors administration & dosage
- Abstract
There are demonstrated results of a prospective comparative study on clinical efficacy and tolerability of Panum (INN: pantoprazole) under the sponsorship of"Unique Pharmaceutical Laboratories (India)". Were evaluated the results of a 28-day course of treatment of 30 patients with GERD, including those with severe reflux esophagitis (erosive and ulcerative), who received 40 mg of pantoprazole as monotherapy. Was found an algorithm with an intermediate control efficacy to individualizing the approach to therapy. As a result 16,7% of patients with severe reflux esophagitis required increasing the dose of pantoprazole to 80 mg/day in two divided doses, and the rest (83,3%) patients to achieve clinical and endoscopic remission of GERD was sufficient single dose of 40 mg of the drug. The results of this study indicated the efficacy and safety of the Panum drug in the treatment of GERD, including its complicated forms.
- Published
- 2011
9. [Results of a multicenter trial "Epidemiology of Gastroesophageal Reflux Disease in Russia" (MEGRE)].
- Author
-
Lazebnik LB, Masharova AA, Bordin DS, Vasil'ev IuV, Tkachenko EI, Abdulkhakov RA, Butov MA, Eremina EIu, Zinchuk LI, and Tsukanov VV
- Subjects
- Adolescent, Adult, Age Factors, Aged, Female, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux drug therapy, Humans, Male, Middle Aged, Prevalence, Russia epidemiology, Surveys and Questionnaires, Young Adult, Gastroesophageal Reflux epidemiology, Population Surveillance
- Abstract
Aim: To assess prevalence of gastroesophageal reflux disease (GERD) in Russia in MEGRE trial in 6 cities of the Russian Federatiion (Kazan, Kemerovo, Krasnoyarsk, Ryazan, St-Petersburg, Saransk)., Material and Methods: Mayo Clinic questionnaire (USA) adapted for Russia was used to question 7812 people over 18 years of age from of random population sample. The symptoms (heartburn and regurgitation) were classified as frequent if they arose once a week and more often for the last 12 months, rare symptoms arose less often than once a week. The responders with frequent heartburn and/or regurgitation were regarded as persons with epidemiological quantitative criteria of GERD., Results: Heartburn occurred in 47.5% responders: frequent in 9%, rare in 38.5%. Regurgitation occurred in 42.9%: frequent in 7.6%, rare in 35.3%. GERD prevalence was 13.3% (city range 11.3-14.3%). Frequent GERD symptoms are associated with frequent gaseous eructation (24.3%), chronic cough (22.9%), chest pain (15.1%), dysphonia (11.4%.). To stop heartburn, 88% responders took antacids, 32%--blockers of histamine H2-receptors and only 23%--inhibitors of proton pump. Only 52.8% responders with frequent chest pain and 29.3% those with frequent heartburn visited a doctor., Conclusion: The population-based trial MEGRE conducted by international methodology in 6 cities of Russia demonstrated that GERD prevalence is 13.3%. Most of the patients pay little attention to the symptoms, do not seek medical advice and, therefore, receive no adequate treatment.
- Published
- 2011
10. [Clinical variants of chronic urticaria associated with Helicobacter pylori].
- Author
-
Sebekina OV, Trubitsyna IE, Masharova AA, and D'iakova EN
- Subjects
- Antibodies, Bacterial blood, Chronic Disease, Female, Helicobacter Infections drug therapy, Helicobacter Infections epidemiology, Helicobacter Infections immunology, Helicobacter pylori drug effects, Helicobacter pylori immunology, Humans, Immunoglobulin A blood, Immunoglobulin E blood, Immunoglobulin G blood, Male, Middle Aged, Recurrence, Treatment Outcome, Urticaria drug therapy, Urticaria epidemiology, Urticaria immunology, Helicobacter Infections complications, Helicobacter pylori isolation & purification, Urticaria complications
- Abstract
Introduction: Chronic urticaria (CU) is one of the toughest problems. The main difficulty is the search for an etiological factor in 70-90% of cases the cause of chronic urticaria remains unclear. In the development and persistence of CU recently paid great importance to the role of Helicobacter pylori infection (HP), which is the most common bacterial infection in humans. However, the influence of HP eradication on the course of CU is poorly understood., Aim: to improve the diagnosis and treatment of urticaria patients with Helicobacter-associated diseases of the upper gastrointestinal tract., Materials and Methods: The study included 184 patients with clinical manifestations of urticaria and HP-associated gastroduodenal pathology in the age of 18., Results: Infection with HP was more frequently detected in patients with chronic idiopathic urticaria in comparison with patients with allergic urticaria (73% and 56% respectively, p < 0.05). In patients with allergic and chronic idiopathic urticaria HP-associating chronic gastritis were detected respectively in 90% and 81% of cases, gastric ulcer (4% and 11%) and duodenal ulcers (6% and 13%) in the first and second groups, respectively (p < 0.05). HP eradication was achieved in 69.2% of patients in the group with AU and 61.8% of patients with CU, while in 20.5% of patients with CU didn't recur in the year. The influence of HP eradication on the course of allergic urticaria isn't established. In order to achieve stable remission CU by HP eradication in patients with diseases of the digestive tract of prognostically important is the combination of the following factors: the initial elevated levels of antibodies to HP (IgG-AP) in the range of 1:360 to 1:900, serum cytokines: interleukin 1beta in the range (68-22 pg/ml) and TNF alpha (84-50 pg/ml), reduced levels of total IgE from 0 to 38 IU/ml., Conclusion: To patients with HP-associated gastrointestinal diseases, combined with idiopathic urticaria is shown holding Helicobacter therapy, because it leads to remission of allergies at 20.5% of patients remaining--to reduce the frequency of exacerbations. To patients with allergic urticaria an HP eradication for the treatment and prevention of AK is not reasonable.
- Published
- 2011
11. [Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
- Author
-
Shcherbakov PL, Ianova OB, Belousova NL, Masharova AA, Shcherbakova MIu, Goncharenko LS, Firsova LD, Kim VA, Govorun VM, and Kashnikov VS
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage, 2-Pyridinylmethylsulfinylbenzimidazoles therapeutic use, Adult, Anti-Infective Agents administration & dosage, Chronic Disease, Clarithromycin administration & dosage, Clarithromycin therapeutic use, Drug Therapy, Combination, Female, Gastritis microbiology, Helicobacter Infections microbiology, Humans, Hydroxybenzoates administration & dosage, Male, Metronidazole administration & dosage, Metronidazole therapeutic use, Nitrofurans administration & dosage, Pantoprazole, Peptic Ulcer microbiology, Treatment Outcome, Anti-Infective Agents therapeutic use, Gastritis drug therapy, Helicobacter Infections drug therapy, Hydroxybenzoates therapeutic use, Nitrofurans therapeutic use, Peptic Ulcer drug therapy
- Published
- 2011
12. [Of the article intraliver pregnancy cholestasis].
- Author
-
Masharova AA and Eremina EIu
- Subjects
- Female, Humans, Pregnancy, Prevalence, Cholestasis, Intrahepatic diagnosis, Cholestasis, Intrahepatic epidemiology, Cholestasis, Intrahepatic therapy, Pregnancy Complications diagnosis, Pregnancy Complications epidemiology, Pregnancy Complications therapy
- Abstract
The article includes the contemporary information about prevalence, clinical history, the methods of diagnostics and treatment of the intraliver pregnancy cholestasis, and about the tactics of the supervision of the pregnant women with intraliver cholestasis.
- Published
- 2011
13. [From the results of the "MEGRE" study to the "Society against heartburn" project].
- Author
-
Bordin DS, Masharova AA, and Lazebnik LB
- Subjects
- Alginates administration & dosage, Alginates therapeutic use, Education, Medical, Continuing, Gastroenterology education, Gastroenterology standards, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux drug therapy, Glucuronic Acid administration & dosage, Glucuronic Acid therapeutic use, Heartburn diagnosis, Heartburn drug therapy, Hexuronic Acids administration & dosage, Hexuronic Acids therapeutic use, Humans, Prevalence, Quality of Life, Russia, Surveys and Questionnaires, Gastroenterology methods, Gastroesophageal Reflux epidemiology, Heartburn epidemiology
- Abstract
This article presents the results of studies "MEGRE" and "VIA APIA", that were made by the Research Institute of Gastroenterology and the Scientific Society of Gastroenterologists of Russia in recent years and a new test for the diagnosis of GERD with a single intake of alginate, which was based on the concept of educational development "Society against heartburn" project.
- Published
- 2011
14. [Prolonged therapy with proton pump inhibitors: balance of benefits and risks].
- Author
-
Lazebnik LB, Bordin DS, and Masharova AA
- Subjects
- Dose-Response Relationship, Drug, Gastric Acid chemistry, Gastric Acid metabolism, Gastric Mucosa drug effects, Gastric Mucosa metabolism, Gastric Mucosa pathology, Humans, Risk, Time Factors, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors adverse effects, Proton Pump Inhibitors therapeutic use
- Published
- 2010
15. [Pharmacokinetics of the proton pump inhibitors and psychological status in patients as factors that influence the efficiency of treatment of GERD with pantoprazole].
- Author
-
Bordin DS, Masharova AA, Sil'vestrova SIu, Firsova LD, Safonova OV, Petrakov AV, Kozhurina TS, Valitova ER, and Ianova OB
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage, 2-Pyridinylmethylsulfinylbenzimidazoles therapeutic use, Adult, Female, Gastroesophageal Reflux diagnosis, Humans, Male, Metabolic Clearance Rate, Pantoprazole, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors therapeutic use, Surveys and Questionnaires, Treatment Outcome, 2-Pyridinylmethylsulfinylbenzimidazoles pharmacokinetics, Attitude to Health, Gastroesophageal Reflux drug therapy, Gastroesophageal Reflux psychology, Proton Pump Inhibitors pharmacokinetics, Quality of Life
- Abstract
Was made an investigation of the effectiveness of pantoprazole (sanpraz, "SanFarma", India) at gastroesophageal reflux disease (GERD). 53 patients with GERD, including 20--with reflux esophagitis, received a daily dose of pantoprazole 40 mg to 28 days. To the 7 day of treatment heartburn was broke in 63.3%, regurgitation--in 65% of patients initially experiencing these symptoms. The 14-th day of treatment heartburn was broke in 83.7%, regurgitation--in 90%. Endoscopic remission in 28-th day of treatment was obtained in 85% of patients with reflux esophagitis. Broking of symptoms was accompanied by significant improvement in well-being and quality of life of patients. Treatment of a standard dose of pantoprazole was ineffective in 16.3% of patients. The reasons for the conservation of heartburn in 4.1% of the cases was an individual characteristics of the pharmacokinetics drug, in 12.2%--non-reflux mechanisms of symptoms in the face of mental status.
- Published
- 2010
16. [Lanzoptol efficacy at gastroesophageal reflux disease: results of multicenter study leader].
- Author
-
Lazebnik LB, Bordin DS, Masharova AA, V'iuchnova ES, Zakharova NV, Abdulkhakov RA, Prokhorova LV, and Nikolaeva NN
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles adverse effects, Adult, Endoscopy, Digestive System, Enzyme Inhibitors adverse effects, Female, Gastroesophageal Reflux pathology, Humans, Hydrogen-Ion Concentration, Lansoprazole, Male, Middle Aged, Remission Induction, Time Factors, 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage, Enzyme Inhibitors administration & dosage, Gastroesophageal Reflux drug therapy
- Abstract
Results of multicenter study "Efficacy of Lansoptol (lansoprazole, KRKA) and its influence on the Dynamics of GERD symptoms" (LIEDER) are presented. The impact of 56-days treatment with lansoprazole 30 mg once daily on symptoms relief, a quality of life of 121 patients with gastroesophageal reflux disease (GERD) and healing of esophageal lesions of 30 patients with reflux esophagitis were investigated. Rapid acid inhibition effect of first dose of lansoptol was shown by 48-hr pH-monitoring. At the first day of the treatment 43.1% of patients reported decreasing of intensity of heartburn and 36.5%--of regurgitation. It were shown that the treatment with lansoptol provided symptoms relief in 25% patients at day 3, in 50% of patients at day 5 and in 75% at day 8 for heartburn, and at days 2, 6 and 9--for regurgitation. It was conducted improvement of quality of life. Healing rate of esophagitis at 28 day was 83.3%.
- Published
- 2010
17. [XXII international session of the european group for the study of helicobacter pylori].
- Author
-
Khomeriki SG, Bordin DS, and Masharova AA
- Subjects
- Europe, Helicobacter Infections, Helicobacter pylori
- Published
- 2010
18. [Helicobacter pylori: prevalence, diagnosis, treatment].
- Author
-
Lazebnik LB, Vasil'ev IuV, Shcherbakov PL, Khomeriki SG, Masharova AA, Badrin DS, Kas'ianenko VI, and Dubtsova EA
- Subjects
- Humans, Prevalence, Helicobacter Infections diagnosis, Helicobacter Infections epidemiology, Helicobacter Infections therapy, Helicobacter pylori
- Published
- 2010
19. [Diagnostic value of alginate test in gastroesophageal reflux disease].
- Author
-
Bordin DS, Masharova AA, Droxzdov VN, Firsova LD, and Kozhurina TS
- Subjects
- Adult, Biocompatible Materials administration & dosage, Drug Combinations, Endoscopy, Digestive System methods, Female, Gastroesophageal Reflux pathology, Gastroesophageal Reflux physiopathology, Glucuronic Acid administration & dosage, Hexuronic Acids administration & dosage, Humans, Hydrogen-Ion Concentration, Male, Middle Aged, Monitoring, Physiologic methods, Alginates administration & dosage, Aluminum Hydroxide administration & dosage, Antacids administration & dosage, Gastroesophageal Reflux diagnosis, Silicic Acid administration & dosage, Sodium Bicarbonate administration & dosage
- Abstract
Aim of Study: To evaluate the diagnostic accuracy of single dose of gaviscon (the alginates test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms., Material and Methods: 123 patients (male 46, female 77, age 43.6 +/- 15.5 years) with symptoms suggestive of GERD were investigated. Symptom response to the alginates test compared in GERD positive and GERD negative patients according traditional diagnostic criteria of GERD (upper endoscopy, 24-hr pH-monitoring, esophageal manometry, response to treatment with PPIs)., Results: Of 91 (78.9%) patients with positive alginates test, 87 were classified as GERD positive and 4 as GERD negative. Of 32 (26%) patients with negative alginates test, 29 were GERD negative and 3 GERD positive. The results providing a sensitivity of alginates test of 96.7% and a specificity of 87.7%., Conclusions: The alginates test is sensitive and specific for diagnosing GERD in patients with typical GERD symptoms.
- Published
- 2010
20. [Gastroesophageal reflux disease in the elderly patients: epidemiology, clinical features, therapy].
- Author
-
Lazebnik LB, Masharova AA, Vasnev OS, Bordin DS, Valitova ÉR, and Ianova OB
- Subjects
- Age Factors, Aged, Aged, 80 and over, Endoscopy methods, Esophagus pathology, Esophagus physiopathology, Female, Humans, Male, Middle Aged, Prevalence, Prospective Studies, Russia epidemiology, Gastroesophageal Reflux epidemiology, Gastroesophageal Reflux pathology, Gastroesophageal Reflux physiopathology, Gastroesophageal Reflux therapy
- Abstract
Aim: Was made a multicenter study of the GERD prevalence in Russia--MEGRE--that revealed quantitative criteria for GERD in 13.3% of respondents but in Moscow it was 23.6%. Also was detected an increasing prevalence with age, and respondents noted a higher prevalence of GERD in groups of older age (over 60) compared with persons younger than 60 years--accordingly 26.5% and 20.2%. We studied the course and treatment of elderly patients with GERD and assessed the results of surgical treatment of patients with short esophagus syndrome., Methods: Was made a prospective study of 500 patients with GERD (241--age 60 years) that were treated with PPI and 95 patients were operated with an axial HH (42 of them with shortening of the esophagus 1-2-th power), mean age 65.7 +/- 17.4 years. We used endoscopic techniques (endoscopy), daily pH monitoring, esophageal manometry., Results: Results of a prospective clinical study in elderly patients allocated two clinical variants of the flow of GERD, predicting a more severe course of disease in patients with a short history (up to 5 years) (the second "adult type") and suggests a differentiated approach to diagnosis and treatment. The expediency of extension to 12 weeks in elderly patients with GERD, the duration of the basic course of PPI therapy in full doses, which increased the effectiveness of therapy in 14.1%. after ending of this protocole, elderly patients with a second type of disease showed maintenance treatment in continuous operation since the regime "on demands from them ineffective. A reasonable approach to therapy in elderly patients, including STIs, can benefit and make a minimal risk of treatment. 24 months after performed fundoplication were observed excellent and good results in 96% of cases. In this case, patients with ineffective esophageal motility observed improvement in esophageal manometry, indicating that nature reflux of these disorders at baseline., Conclusions: Course and treatment of GERD in the elderly has its own characteristics, which dictate the need for an integrated approach to diagnosis and treatment of these patients. Older patients with esophageal shortening, 1 st degree possible to perform laparoscopic surgery, and shortening of the esophagus, 2 nd degree is the most secure laparotomic access.
- Published
- 2010
21. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
- Author
-
Lazebnik LB, Bordin DS, Masharova AA, Dzhulaĭ GS, Butov MA, Abdulkhakov RA, Eremina EIu, Tarasova LV, Safonova OV, Firsova LD, and Kozhurina TS
- Subjects
- Adult, Alginates administration & dosage, Aluminum Hydroxide administration & dosage, Antacids administration & dosage, Drug Combinations, Female, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux prevention & control, Gastroesophageal Reflux psychology, Heartburn diagnosis, Heartburn prevention & control, Heartburn psychology, Humans, Male, Prospective Studies, Severity of Illness Index, Silicic Acid administration & dosage, Sodium Bicarbonate administration & dosage, Surveys and Questionnaires, Suspensions, Treatment Outcome, Alginates therapeutic use, Aluminum Hydroxide therapeutic use, Antacids therapeutic use, Gastroesophageal Reflux drug therapy, Heartburn drug therapy, Quality of Life psychology, Silicic Acid therapeutic use, Sodium Bicarbonate therapeutic use
- Abstract
Was conducted a muIticenter study VIA APIA, in which the impact of gaviscon forte (suspension) on symptoms, general state and quality of life of 148 patients (male 53, female 95, age 42.9 +/- 15.6) with gastroesophageal reflux disease (GERD) were investigated. The patients had undergone clinical evaluation of dynamics of GERD symptoms (Likert scale), general state (Visual Analogue Scale, questionnaire SAN) and quality of life (SF-36). It was shown that 14-days treatment with gaviscon forte provided symptoms relief in 84.5% patients and conducted improvement of general state and quality of life. Gaviscon forte recommended as drug of choice in initial treatment for the first time visited patient with heartburn before endoscopy and for pathogenetic treatment of typical reflux syndrome.
- Published
- 2010
22. [Functional methods of the esophagus examination].
- Author
-
Valitova ER, Bordin DS, Ianova OB, Vasnev OS, and Masharova AA
- Subjects
- Electric Impedance, Esophageal Motility Disorders metabolism, Esophagus metabolism, Esophagus physiology, Gastric Acidity Determination, Gastroesophageal Reflux metabolism, Humans, Hydrogen-Ion Concentration, Manometry, Esophageal Motility Disorders diagnosis, Esophagus physiopathology, Gastroesophageal Reflux diagnosis, Monitoring, Physiologic methods
- Abstract
Manometry of the esophagus is the "gold standard" in diagnosing diseases of the esophagus associated with motor disorders. The combination of manometry with impedance gives an indication of violation of bolus transport along the esophagus. High resolution manometry is new method that provides the most accurate information about the functional anatomy of the esophagus and its sphincters, as well as accurately characterizes the esophageal-gastric junction. We can increase the diagnostic value of daily pH-monitoring by analyzing communication with reflux symptoms. The combination of pH and impedance can identify different types of reflux (acid, sour, gas, liquid and mixed) in patients with symptoms of GERD and related Ahil, after gastric resection in children and infants, to evaluate the effectiveness of antireflux therapy.
- Published
- 2010
23. [Multicentre study "Epidemiology of gastroesophageal reflux disease in Russia"(MEGRE): first results].
- Author
-
Lazebnik LB, Masharova AA, Bordin DS, Vasil'ev IuV, Tkachenko EI, Abdulkhakov RA, Butov MA, Eremina EIu, Zinchuk LI, and Tsukanov VV
- Subjects
- Adult, Age Factors, Aged, Chest Pain epidemiology, Chest Pain physiopathology, Cough epidemiology, Cough physiopathology, Dyspepsia epidemiology, Dyspepsia physiopathology, Eructation epidemiology, Eructation physiopathology, Female, Gastroesophageal Reflux physiopathology, Heartburn epidemiology, Heartburn physiopathology, Humans, Male, Middle Aged, Prevalence, Russia epidemiology, Gastroesophageal Reflux epidemiology, Surveys and Questionnaires
- Abstract
We aimed to determine the prevalence and clinical spectrum of GERD in the urban population of 6 cities in different parts of Russia (St. Petersburg, Ryazan, Kazan, Kemerovo, Krasnoyarsk and Saransk). A previously validated reflux questionnaire developed at the Mayo Clinic was translated into Russian, culturally adapted and administered. Data was collected from 7812 randomly selected subjects greater than 18 years old with the assistance of the yellow pages. 'Frequent symptoms' were defined as a major symptom (heartburn and/or regurgitation) occurring at least once a week or more. "Occasional symptoms" were defined as an episode of one of the major symptoms occurring less than once a week within the past 12 months. Patients were defined as having GERD if they reported frequent heartburn and/or regurgitation. The average prevalence of frequent and occasional GERD symptoms in Russia was 9% and 38.5% for heartburn and 7.6% and 35.3% for regurgitation respectively within the last 12 months. The average prevalence of GERD in Russia was 13.3% (11.3-14.3%). The prevalence of frequent heartburn decreased with age (r = -0.3); however, frequent regurgitation increased (r = 0.7) with age. As a result, we found that prevalence of GERD increased with age. The average prevalence of GERD was statistically the same in men (12.5%) and in women (13.9%). This prevalence didn't change with age in men but did increase with age in elderly women to 24%. Frequent heartburn and regurgitation (GERD) were significantly associated with frequent belching (24.3%), chronic cough (22.9%), dyspepsia (19.8%), non-cardiac chest pain (15.1%), nausea (14.9%), hoarseness (11.4%), dysphagia (8.1%), odynophagia (7.3%) and constipation (37.8%). Alcohol consumption (prevalence of 60.4% among respondents) and smoking (prevalence of 25.4% among respondents) didn't yield any significant difference in subjects with frequent symptoms. Importantly, we also found that only 52.8% of subjects with frequent chest pain and 29.3% of respondents with frequent heartburn had seen a physician for these symptoms.
- Published
- 2009
24. [Prevention of intestinal dysbiosis in patients after anti-Helicobacter therapy].
- Author
-
Masharova AA and Eremina EIu
- Subjects
- Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents therapeutic use, Helicobacter Infections complications, Helicobacter Infections drug therapy, Humans, Intestinal Diseases etiology, Intestinal Diseases microbiology, Peptic Ulcer complications, Peptic Ulcer drug therapy, Probiotics administration & dosage, Anti-Bacterial Agents adverse effects, Intestinal Diseases prevention & control, Prebiotics, Probiotics therapeutic use
- Abstract
This article presents a literature review of side effects of antihelikobakter therapy, as well as survey data, whose goal was to determine the efficacy and safety of normoflorins at patients after eradication therapy of peptic ulcer. It was shown that the frequency of occurrence of side effects during antihelikobakter therapy varies widely and can reach, according to different authors, from 30 to 50% of patients. In addition to allergic and toxic PE, with antibacterial agents allocate their influence on the microflora of the colon, which often leads to development of a scarce and dysbacteriosis of antibioticassociated colitis. Appointment of biodiesel of normoflorin after eradication therapy effectively suppresses clinical signs of dyspepsia as a side effect of antihelikobakter therapy enhances the effectiveness of treatment of patients and improve their quality of life.
- Published
- 2009
25. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
- Author
-
Bordin DS, Masharova AA, Firsova LD, Kozhurina TS, and Safonova OV
- Subjects
- Adult, Alginates administration & dosage, Aluminum Hydroxide administration & dosage, Antacids administration & dosage, Cross-Over Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Female, Gastroesophageal Reflux psychology, Heartburn psychology, Humans, Male, Middle Aged, Quality of Life psychology, Silicic Acid administration & dosage, Sodium Bicarbonate administration & dosage, Taste, Time Factors, Treatment Outcome, Alginates therapeutic use, Aluminum Hydroxide therapeutic use, Antacids therapeutic use, Gastroesophageal Reflux drug therapy, Heartburn drug therapy, Silicic Acid therapeutic use, Sodium Bicarbonate therapeutic use
- Abstract
We conducted a crossover study, in which the efficacy and the onset of action of a single dose of Gaviscon (suspension) and Gaviscon forte (suspension) in 52 patients with heartburn of moderate intensity and gastroesophageal reflux disease (GERD) have been investigated. The average age of the patients was 44.0 +/- 17.3-years-old. The patients have undergone clinical evaluation of intensity of GERD symptoms and psychological assessment (questionnaires SF-36, SMOL, LOBI). Alginates' effects and qualities were evaluated using stopwatch technique, clinical examination, and organoleptic assessment. Primary sensation of a cooling (soothing) effect after use of a single dose of Gaviscon has been reported in 65.7 seconds (on average), and Gaviscon forte--in 66.1 seconds. Fourty three (82.7%) patients with heartburn have described the effects of both medications as "instant" cooling effects. Heartburn was relieved in 3.3 minutes in all patients after a single dose of Gaviscon, and in 3.6 minutes in 51 (98.1%) patients who have received a single dose of Gaviscon forte. Organoleptic qualities averaged at 3.6 points (on a scale of 1-5) for Gaviscon, and at 3.5 points for Gaviscon forte. Assessment of mental status of the patients suggested that a "delayed" effect of the medications in relieving heartburn in some patients may have occurred due to possible physical disadaptation.
- Published
- 2009
26. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
- Author
-
Bordin DS, Masharova AA, Firsova LD, Kozhurina TS, and Safonova OV
- Subjects
- Alginates administration & dosage, Alginates adverse effects, Aluminum Hydroxide administration & dosage, Aluminum Hydroxide adverse effects, Antacids administration & dosage, Antacids adverse effects, Drug Administration Schedule, Drug Combinations, Female, Gastric Acid metabolism, Gastric Acidity Determination, Gastric Mucosa metabolism, Gastroesophageal Reflux diagnosis, Humans, Hydrogen-Ion Concentration, Male, Middle Aged, Quality of Life, Silicic Acid administration & dosage, Silicic Acid adverse effects, Sodium Bicarbonate administration & dosage, Sodium Bicarbonate adverse effects, Alginates therapeutic use, Aluminum Hydroxide therapeutic use, Antacids therapeutic use, Gastric Mucosa drug effects, Gastroesophageal Reflux drug therapy, Silicic Acid therapeutic use, Sodium Bicarbonate therapeutic use
- Published
- 2008
27. [Long-term therapy of acid-dependent diseases with proton pump inhibitors and risk of colorectal cancer (literature review)].
- Author
-
Bordin DS, Masharova AA, and Lazebnik LB
- Subjects
- Clinical Trials as Topic, Colorectal Neoplasms metabolism, Gastrins blood, Gastroesophageal Reflux metabolism, Humans, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors therapeutic use, Risk Factors, Colorectal Neoplasms chemically induced, Gastroesophageal Reflux drug therapy, Proton Pump Inhibitors adverse effects
- Published
- 2008
28. [Characteristics of gastric secretory and motor functions in gastroesophageal reflux disease with constipations].
- Author
-
Lychkova AE, Ianova OB, and Masharova AA
- Subjects
- Adult, Aged, Constipation complications, Constipation metabolism, Female, Gastroesophageal Reflux complications, Gastroesophageal Reflux metabolism, Humans, Male, Middle Aged, Prospective Studies, Constipation physiopathology, Gastric Acid metabolism, Gastroesophageal Reflux physiopathology, Gastrointestinal Motility physiology
- Published
- 2008
29. [Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
- Author
-
Bordin DS and Masharova AA
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles administration & dosage, 2-Pyridinylmethylsulfinylbenzimidazoles pharmacology, Dose-Response Relationship, Drug, Drug Administration Schedule, Gastric Acidity Determination, Humans, Hydrogen-Ion Concentration, Lansoprazole, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors pharmacology, Treatment Outcome, 2-Pyridinylmethylsulfinylbenzimidazoles therapeutic use, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux drug therapy, Proton Pump Inhibitors therapeutic use
- Published
- 2008
30. [Prevalence of gastroesophageal reflux disease in Moscow: results of a population study].
- Author
-
Lazebnik LB, Vasil'ev IuV, Masharova AA, and Manannikov IV
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Moscow epidemiology, Prevalence, Retrospective Studies, Risk Factors, Gastroesophageal Reflux epidemiology, Population Surveillance methods, Urban Population
- Abstract
Aim: To study prevalence of the principal symptoms of gastroesophageal reflux disease (GERD) in Moscow., Material and Methods: A total of 1065 respondents aged 15-85 years (a random representative sample of population of one of the typical Moscow districts) participated in a questionnaire survey using the international questionnaire for detection of GERD incidence., Results: Epigastric burning (EB) occurs in 39.6% examinees. GERD prevalence is 14.2%. Subjects with EB have the following symptoms of GERD: regurgitation (66.3%), epigastric pain (discomfort) (53.0%), nausea (43.6%), vomiting (23.2%), dysphagia (20.6%), chest pain (18.0%), odinophagia (5.5%), singultus (4.6%). There is a direct correlation between incidence rate of EB, height, body mass index, number of alcohol excesses and smoked cigarettes., Conclusion: EB occurs in both young and aged men and women with similar frequency. Significant differences were detected only in the age group 45-59 years in which EB is more frequent in women. All the symptoms excluding cough and singultus were seen in women significantly more frequently. With age, these differences disappeared but noncardial pain in the chest that was less frequent in the elderly. Muscovites with GERD symptoms are older (61.26 +/- 13.47 years) than those without such symptoms (58.44 +/- 16.28, p < 0.0001).
- Published
- 2008
31. [Society against heartburn].
- Author
-
Lazebnik LB, Bordin DS, and Masharova AA
- Subjects
- Antacids administration & dosage, Antacids therapeutic use, Anti-Ulcer Agents administration & dosage, Anti-Ulcer Agents therapeutic use, Drug Utilization, Gastroesophageal Reflux complications, Gastroesophageal Reflux epidemiology, Humans, Russia, Surveys and Questionnaires, Heartburn drug therapy, Heartburn epidemiology, Heartburn etiology, Primary Health Care methods
- Published
- 2007
32. [Modern concept of gastroesofageal reflux disease: from Genvaal to Monreal].
- Author
-
Lazebnik LB, Bordin DS, and Masharova AA
- Subjects
- Congresses as Topic, Gastroesophageal Reflux diagnosis, Humans, Evidence-Based Medicine, Gastroesophageal Reflux etiology
- Published
- 2007
33. [Characteristics of gastroesophageal reflux disease in elderly people].
- Author
-
Masharova AA and Bordin DS
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Barrett Esophagus epidemiology, Barrett Esophagus etiology, Esophageal Stenosis epidemiology, Esophageal Stenosis etiology, Gastric Acid metabolism, Gastric Mucosa metabolism, Histamine H2 Antagonists administration & dosage, Histamine H2 Antagonists therapeutic use, Humans, Middle Aged, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors therapeutic use, Stomach drug effects, Aging, Gastroesophageal Reflux complications, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux drug therapy, Gastroesophageal Reflux epidemiology
- Published
- 2007
34. [Pharmacoeconomic aspects of the use of proton pump inhibitors].
- Author
-
Lazebnik LB, Masharova AA, and Guseĭnzade MG
- Subjects
- Humans, Anti-Ulcer Agents therapeutic use, Digestive System Diseases drug therapy, Digestive System Diseases economics, Health Care Costs, Proton Pump Inhibitors
- Published
- 2006
35. [New alternative drug therapy for reducing symptoms associated with the functional gastric disorders].
- Author
-
Vasil'ev IuV, Masharova AA, and Ianova OB
- Subjects
- Adult, Betaine therapeutic use, Female, Humans, Male, Treatment Outcome, Betaine analogs & derivatives, Dyspepsia drug therapy, Stomach Diseases drug therapy
- Published
- 2005
36. [H2-blockers of histamine receptors in the therapy of early stages of gastroduodenal reflux disease].
- Author
-
Lazebnik LB, Vasil'ev IuV, Masharova AA, Zelenkin SA, and Ianova OB
- Subjects
- Adolescent, Adult, Aged, Duodenogastric Reflux diagnosis, Endoscopy, Gastrointestinal, Humans, Male, Middle Aged, Treatment Outcome, Duodenogastric Reflux drug therapy, Famotidine therapeutic use, Histamine H2 Antagonists therapeutic use
- Abstract
The efficacy of the administration of famotidine, 20 mg BID, at early stages of gastroduodenal reflux disease (GDRD) based on a clinical and endoscopy study and treatment of patients of 0 and 1 degrees on the modified Savary-Miller scale.
- Published
- 2004
37. [Tolerance and safety of anti-Helicobacter drugs in the treatment of ulcer disease].
- Author
-
Artamonov VE, Masharova AA, Gorodetskiĭ VV, and Vertkin AL
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Anti-Ulcer Agents therapeutic use, Antibiosis drug effects, Autonomic Nervous System drug effects, Colon drug effects, Colon microbiology, Digestive System innervation, Female, Helicobacter Infections microbiology, Humans, Male, Middle Aged, Peptic Ulcer microbiology, Treatment Outcome, Anti-Bacterial Agents adverse effects, Anti-Ulcer Agents adverse effects, Digestive System drug effects, Dyspepsia chemically induced, Helicobacter Infections drug therapy, Helicobacter pylori drug effects, Peptic Ulcer drug therapy
- Abstract
132 patients (mean age 46.9 +/- 1.4 years) with exacerbation of gastroduodenal ulcer (GDU) positive by Helicobacter pylori (HP) were examined clinically and using laboratory tests. All the patients received treatment with anti-HP drugs. Side effects were registered in 81(61.4%) patients. Negative trend in colon biocenosis occurred in all the patients. The treatment was poorly tolerated by women, aged patients and those with ulcer in the stomach. Biocenosis aggravation is indication for administration of eubiotics.
- Published
- 2001
38. [Josamycin combination with ranitidine in therapy of gastroduodenal ulcer: clinical efficiency].
- Author
-
Maev IV, Vertkin AL, Vovk EI, Masharova AA, Bezborodnyĭ SD, and Lebedeva EG
- Subjects
- Adult, Drug Therapy, Combination, Duodenal Ulcer microbiology, Female, Helicobacter Infections drug therapy, Helicobacter Infections microbiology, Humans, Male, Stomach Ulcer microbiology, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Duodenal Ulcer drug therapy, Histamine H2 Antagonists therapeutic use, Josamycin therapeutic use, Ranitidine therapeutic use, Stomach Ulcer drug therapy
- Abstract
Efficacy of a novel eradication treatment with ranitidine, trichopol and jozamycin was compared to that of the standard three-component therapy and monotherapy with ranitidine in 76 patients with exacerbation of gastric and duodenal ulcer. Therapeutic monitoring of ranitidine was performed. In relation to healing of ulcer defect and eradication of Helicobacter pylori, jozamycin is not less effective and more safe than standard three-component therapy. Interaction of the scheme components increases plasma concentration of ranitidine especially in patients with concomitant hepatic and renal diseases.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.